Advanced search
Publication Cover
mAbs Volume 11, 2019 - Issue 4
Submit an article Journal homepage
4,581
Views
3
CrossRef citations to date
0
Altmetric
Report

Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy

Hongchuan LiuDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaView further author information
,
Lijing GuoInstitute of Physical Science and Information Technology, Anhui University, Hefei, China;CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, BeijingChinaView further author information
,
Jing ZhangDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaView further author information
,
Yuehua ZhouDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaView further author information
,
Jinwei ZhouDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaView further author information
,
Jian YaoDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaORCID Iconhttps://orcid.org/0000-0001-7293-7140View further author information
ORCID Icon,
Hai WuDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaView further author information
,
Sheng YaoDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaORCID Iconhttps://orcid.org/0000-0001-7293-7140View further author information
ORCID Icon,
Bo ChenDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaView further author information
,
Yan ChaiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0002-1912-3620View further author information
ORCID Icon,
Jianxun QiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaView further author information
,
George F. GaoCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaView further author information
,
Shuguang TanInstitute of Physical Science and Information Technology, Anhui University, Hefei, China;CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaCorrespondence[email protected] [email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-2599-4959View further author information
ORCID Icon,
Hui FengDepartment of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaCorrespondence[email protected] [email protected] [email protected]
View further author information
&
Jinghua YanInstitute of Physical Science and Information Technology, Anhui University, Hefei, China;CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, BeijingChina;CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaCorrespondence[email protected] [email protected] [email protected]
View further author information
 show all
Pages 681-690 | Received 01 Jan 2019, Accepted 12 Mar 2019, Published online: 19 Apr 2019

References

  • Tan S, Gao GF. New hope for cancer treatment: cancer immunotherapy. Chinese Sci Bull. 2015;60:3155–57. In Chinese.
  • Callahan MK Postow MA and Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity. 2016;44:1069–78. doi:10.1016/j.immuni.2016.04.023.
  • Ishida Y, Agata Y, Shibahara K and Honjo H. Induced Expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell-death. EMBO J. 1992;11:3887–95.
  • Nishimura H, Nose M, Hiai H, Minato N and Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–51.
  • Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.
  • Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T and Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–97. doi:10.1073/pnas.192461099.
  • Curiel TJ, Wei S, Dong HD, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–67. doi:10.1038/nm863.
  • Hirano F, Kaneko K, Tamura H, Dong HD, Wang SD, Ichikawa, Rietz C, Flies DB, Lau JS, Zhu GF, Tamada K, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089–96.
  • Passaro C, Alayo Q, DeLaura I, McNulty JJ, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, et al. Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin Cancer Res. 2018. doi:10.1158/1078-0432.CCR-18-2311.
  • Mahoney KM, Rennert PD and Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–84. doi:10.1038/nrd4591.
  • Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–56. doi:10.1038/nbt.4195.
  • Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016;7:13354. doi:10.1038/ncomms13354.
  • Liu K, Tan S, Chai Y, Chen D, Song H, C W Z, Shi Y, Liu J, Tan W, Lyu J, et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 2016;27:151–53. doi:10.1038/cr.2016.102.
  • He M, Chai Y, Qi J, C W Z, Tong Z, Shi Y, Yan J, Tan S and Gao GF. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget. 2017;8:67129–39. doi:10.18632/oncotarget.18004.
  • Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, Qi J, Wong G, Zhu X, Liu WJ, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017;8:14369. doi:10.1038/ncomms14369.
  • Na Z, Yeo SP, Bharath SR, Bowler MW, Balikci E, Wang CI and Song H. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 2017;27:147–50. doi:10.1038/cr.2016.77.
  • Tan S, Liu K, Chai Y, Zhang CW, Gao S, Gao GF and Qi J. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9:135–39. doi:10.1007/s13238-017-0412-8.
  • Tan S, Zhang CW and Gao GF. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduct Target Ther. 2016;1:16029. doi:10.1038/sigtrans.2016.29.
  • Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3:17004. doi:10.1038/celldisc.2017.4.
  • Tan S, Chen D, Liu K, He M, Song H, Shi Y, Liu J, Zhang CW, Qi J, Yan J, et al. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell. 2016;7:866–77. doi:10.1007/s13238-016-0337-7.
  • Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55. doi:10.1038/nrc3982.
  • Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33:187–201. doi:10.1016/j.ccell.2018.01.009.
  • Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, et al. Melanoma cell-intrinsic pd-1 receptor functions promote tumor growth. Cell. 2015;162:1242–56. doi:10.1016/j.cell.2015.08.052.
  • Fu J, Wang F, Dong LH, Zhang J, Deng CL, Wang XL, Xie XY, Zhang J, Deng RX, Zhang LB, et al. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of Toripalimab, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin. 2017;38:710–18. doi:10.1038/aps.2016.161.
  • Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N and Garboczi DN. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A. 2008;105:3011–16. doi:10.1073/pnas.0712278105.
  • Lazar-Molnar E, Yan Q, Cao E, Ramagopal U, Nathenson SG and Almo SC. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A. 2008;105:10483–88. doi:10.1073/pnas.0804453105.
  • Xu C, Ng DT. Glycosylation-directed quality control of protein folding. Nat Rev Mol Cell Biol. 2015;16:742–52. doi:10.1038/nrm4073.
  • Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26.
  • Read RJ. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr. 2001;57:1373–82.
  • Collaborative computational project N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50:760–63. doi:10.1107/S0907444994003112.
  • Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–32. doi:10.1107/S0907444904019158.
  • Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213–21. doi:10.1107/S0907444909052925.
  • Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12–21. doi:10.1107/S0907444909042073.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.